- Home
- RSF vs UNCY Comparison
RSF vs UNCY Comparison
Compare RSF & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- UNCY
- Stock Information
- Founded
- RSF 2016
- UNCY 2016
- Country
- RSF United States
- UNCY United States
- Employees
- RSF N/A
- UNCY N/A
- Industry
- RSF Investment Managers
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- RSF Finance
- UNCY Health Care
- Exchange
- RSF Nasdaq
- UNCY Nasdaq
- Market Cap
- RSF 63.1M
- UNCY 74.2M
- IPO Year
- RSF N/A
- UNCY 2021
- Fundamental
- Price
- RSF $14.69
- UNCY $5.00
- Analyst Decision
- RSF
- UNCY Strong Buy
- Analyst Count
- RSF 0
- UNCY 5
- Target Price
- RSF N/A
- UNCY $55.20
- AVG Volume (30 Days)
- RSF 11.8K
- UNCY 395.5K
- Earning Date
- RSF 01-01-0001
- UNCY 11-12-2025
- Dividend Yield
- RSF 10.61%
- UNCY N/A
- EPS Growth
- RSF N/A
- UNCY N/A
- EPS
- RSF N/A
- UNCY N/A
- Revenue
- RSF N/A
- UNCY N/A
- Revenue This Year
- RSF N/A
- UNCY N/A
- Revenue Next Year
- RSF N/A
- UNCY $19,912.34
- P/E Ratio
- RSF N/A
- UNCY N/A
- Revenue Growth
- RSF N/A
- UNCY N/A
- 52 Week Low
- RSF $14.81
- UNCY $3.71
- 52 Week High
- RSF $16.23
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- RSF 44.48
- UNCY 64.95
- Support Level
- RSF $14.65
- UNCY $4.69
- Resistance Level
- RSF $14.92
- UNCY $5.34
- Average True Range (ATR)
- RSF 0.12
- UNCY 0.32
- MACD
- RSF -0.01
- UNCY 0.04
- Stochastic Oscillator
- RSF 16.64
- UNCY 72.52
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.